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a b s t r a c t
Background: Immunoglobulin A (IgA) is the predominant antibody produced in response to mucosal
infections. The role of IgA in providing protection against inﬂuenza in children vaccinated with live
attenuated inﬂuenza vaccine (LAIV) has not been well described.
Methods: Nasal IgA responses were assessed using data from 3 prospective, 2-year, randomized studies
comparing LAIV with placebo in children 6–36 months of age. In each study, samples were collected in a
subset of patients; a new cohort was enrolled each year. Ratios of strain-speciﬁc nasal IgA to total nasal
IgA were calculated and prevaccination to postvaccination geometric mean fold-rises (GMFRs) were
evaluated. Mean postvaccination IgA ratios were compared for subjects with and without conﬁrmed
inﬂuenza illness by study and in pooled analyses.
Results: Across studies, a higher percentage of children receiving LAIV had a ≥2-fold increase in strain-
speciﬁc IgA ratio compared with placebo recipients. GMFRs after LAIV in years 1 and 2 ranged from 1.2
to 6.2, compared with 0.5–2.2 among placebo recipients. Similar responses were observed in subjects
who were baseline seronegative and seropositive based on serum hemagglutination inhibition antibody
titers. In years 1 and 2, the mean postvaccination strain-speciﬁc to total IgA ratio was 3.1-fold (P<0.01)
and 2.0-fold (P<0.03) higher among LAIV recipients with no evidence of culture-conﬁrmed inﬂuenza
illness compared with LAIV recipients who developed culture-conﬁrmed inﬂuenza illness; a similar and
consistent trend was observed for each individual study and type/subtype.
Conclusions: The current analysis demonstrates that nasal IgA contributes to the efﬁcacy of LAIV and can
provide evidence of vaccine-induced immunity. However, the inherent heterogeneity in nasal antibody
levels and variability in nasal specimen collection hinders the precise evaluation of mucosal antibody
responses. Other studies have demonstrated that LAIV-induced immunity is also partially explained by
T-cell immunity, serum antibody responses, and innate immunity, consistent with the multi-faceted
ced bnature of immunity indu
. Introduction
Infection with wild-type inﬂuenza induces immunity to subse-
uent infectionwith antigenically related strains primarily through
erum and mucosal antibodies. While serum antibodies are gen-
rally responsible for lower respiratory tract protection, local
ucosal antibodies are critical for protection of the upper respi-
atory tract. T-cell and innate immune responses also contribute
o protection and reductions in illness severity [1–3]. In order to
revent inﬂuenza illness, vaccination has long been established as
he preferred approach [4].
∗ Corresponding author at: MedImmune, LLC, One MedImmune Way,
aithersburg, MD 20878, USA. Tel.: +1 301 398 4454; fax: +1 301 398 9454.
E-mail address: ambrosec@medimmune.com (C.S. Ambrose).
264-410X © 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
ttp://dx.doi.org/10.1016/j.vaccine.2012.09.018y wild-type inﬂuenza infection and other live virus vaccines.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
An Ann Arbor strain live attenuated inﬂuenza vaccine (LAIV;
MedImmune, LLC,Gaithersburg,MD) is licensed foruse in anumber
of countries in eligible individuals 2–49years of age [5]; in theEuro-
pean Union, LAIV is approved for use in children 2–17 years of age;
in Canada, LAIV is approved for individuals 2–59 years of age. LAIV
has been shown to be effective in preventing culture-conﬁrmed
inﬂuenza illness in children and adults [6–8]; in children, stud-
ies have demonstrated that LAIV provides greater protection than
standard inactivated inﬂuenza vaccines [9–12]. However, despite
multiple immunologic investigations, robust immunologic corre-
lates of protection have not been established for LAIV.
Although functional serum antibody titers as measured by
hemagglutination inhibition (HAI) are generally regarded as the
correlate of protection for inactivated inﬂuenza vaccines, the gen-
eral trend observed in studies of LAIV-induced immune responses
is that adults demonstrate limited serum antibody responses to
LAIV; by comparison, young children, particularly those without
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re-existing antibodies, can exhibit higher rates of seroconver-
ion in response to vaccination [13–21]. Studies have demonstrated
hat LAIV can induce protective immunity in the absence of robust
erum antibody responses [22–25]. Studies have also demonstrated
hat LAIV induces mucosal antibody responses [26,27] and T-cell
esponses [17,28–30] that may  contribute to protective immunity.
Immunoglobulin A (IgA) is the predominant antibody at mucosal
urfaces, with both extracellular and intracellular activity [31], and
igh levels of anti-inﬂuenza antibody secreting cells have been
emonstrated in the nasal mucosa in adults with a history of
revious wild-type inﬂuenza exposures [32]. A recent study of chil-
ren with severe inﬂuenza disease suggested that anti-inﬂuenza
ucosal antibody may  be particularly important in children [33].
here is also evidence that IgA may  be more cross-reactive against
ntigenically drifted inﬂuenza viruses than IgG [34].
Although a previous study demonstrated IgA responses follow-
ng LAIV, the relationship between IgA responses and the incidence
f inﬂuenza illness was not evaluated [27]. Three previous random-
zed, placebo-controlled clinical studies of LAIV efﬁcacy in young
hildren prospectively evaluated postvaccination IgA responses in
 subset of study subjects [14,20,35]. This analysis describes the
train-speciﬁc IgA responses observed in these 3 studies and exa-
ines the relationship between IgA and the incidence of inﬂuenza
llness.
. Methods
.1. Subjects
Nasal IgA responses were evaluated using data from 3 prospec-
ive, 2-year, randomized, placebo-controlled studies of LAIV in
hildren. The detailed methods and inclusion/exclusion criteria
or each study have been previously published. Study 1 was a 2-
ear study conducted in inﬂuenza vaccine-naive children 12 to <36
onths of age from 2000 to 2002 in Asia [20]. Study 2 [35] was con-
ucted in inﬂuenza vaccine-naive children 6 to <36 months of age
ttending day care in several European countries and Israel from
000 to 2002. Study 3 [14] was conducted in inﬂuenza vaccine-
aive children 6 to <36 months of age in South America and South
frica in 2001–2002. In studies 1 and 2, children were randomized
o 2 doses of vaccine or placebo approximately 1 month apart in
ear 1. In study 3, there were 3 randomized treatment groups in
ear 1:2 doses of vaccine approximately 1 month apart, 1 dose of
accine followed by 1 dose of placebo approximately 1 month later,
nd 2 doses of placebo approximately 1 month apart. In all 3 stud-
es, subjects received a single dose of vaccine or placebo in year 2
14]. The vaccines and placebos used in each study are described in
upplementary Text 1.
.2.  Nasal IgA evaluation
In  all studies, nasal IgA and serum HAI antibody titers were
valuated in a subset of subjects enrolled. A separate population
as deﬁned each year. Nasal wash and serum samples were col-
ected from subjects on 4 occasions over the 2 years: immediately
efore the ﬁrst dose in year 1, approximately 1 month after the
econd dose in year 1, immediately before the year 2 dose, and
pproximately 1 month after the year 2 dose. In study 3, due to the
andomization of subjects to 1 versus 2 doses of vaccine in the ﬁrst
ear, additional samples were collected from subjects immediately
efore the second dose in year 1.
Nasal wash samples were tested by enzyme-linked immunosor-
ent assay (ELISA) for total IgA and strain-speciﬁc IgA antibody to
he inﬂuenza A/H1N1, A/H3N2 and B vaccine strains. The primary
ndpoint for the IgA analysis was the ratio of inﬂuenza-speciﬁc IgA30 (2012) 6794– 6801 6795
against A/H1N1, A/H3N2, or B strains in the vaccine to total IgA
antibody. Geometric mean titers (GMTs) of absolute strain-speciﬁc
IgA and total IgA were also evaluated at all time points. For strain-
speciﬁc and total IgA, values for samples with no IgA were imputed
as 50% of the minimum detectable value. Detailed methodologies
and speciﬁc reagents used for this analysis are available in Supple-
mentary Text 1. Serum antibody titers were evaluated by HAI assay
using standard methods, as previously described [14,20]. Seroneg-
ative subjects were deﬁned as those with a prevaccination HAI
antibody titer of 4 or less; seropositive subjects were those with
a titer greater than 4. An HAI response was deﬁned as a 4-fold
increase from prevaccination to postvaccination.
For descriptive purposes, the IgA response was  categorized
using 3 measurements: the percentages of subjects with ≥2-fold
and ≥4-fold increases in the ratio of strain-speciﬁc to total IgA from
baseline and the geometric mean fold rise (GMFR) in the ratio of
strain-speciﬁc to total IgA from baseline. Results were evaluated
separately for each study. The correlation between nasal IgA and
serum HAI antibody responses was evaluated across studies for
each inﬂuenza type/subtype.
To  examine the relationship between IgA and the incidence of
inﬂuenza illness, geometric mean postvaccination IgA ratios were
compared between subjects with culture-conﬁrmed inﬂuenza ill-
ness and those without evidence of culture-conﬁrmed inﬂuenza
illness. Inﬂuenza illness was  evaluated for any inﬂuenza strain
regardless of antigenic match to the vaccine as well as due to
vaccine-matched strains. LAIV and placebo recipients were eval-
uated separately for each study. Additionally, given the small size
of the immunogenicity cohorts in each study and the similarities
in the design of the studies, a pooled analysis of all 3 studies was
conducted to increase the statistical power to detect an effect. Only
studies with at least 1 case of inﬂuenza illness were pooled.
Statistical comparison tests were conducted at the signiﬁcance
level of 0.05 using Fisher’s exact test for the proportion of subjects
with a ≥2-fold increase in titers and using the two-sample t-test
for GMFRs and geometric means.
3. Results
3.1. Study subjects
In  year 1, there were 183 (107 LAIV, 76 placebo), 101 (64 LAIV,
37 placebo), and 333 (226 LAIV, 107 placebo) subjects in studies 1,
2, and 3, respectively, with IgA data available for analysis. In year
2, there were 175 (94 LAIV, 81 placebo), 41 (24 LAIV, 17 placebo),
and 791 (528 LAIV, 263 placebo) subjects in studies 1, 2, and 3,
respectively. In each study, LAIV and placebo recipients were well-
matched in regards to age and sex.
3.2. Increases in strain-speciﬁc IgA
Across the 3 studies, approximately one month after the sec-
ond dose, a higher percentage of LAIV recipients had a ≥2-fold
increase in strain-speciﬁc IgA ratio compared with placebo recipi-
ents (Fig. 1). In many comparisons, the difference between LAIV and
placebo recipients was  statistically signiﬁcant. In study 3, responses
were observed after a single dose but the differences compared to
placebo recipients were more apparent after receipt of 2 doses of
vaccine. Among subjects receiving only 1 dose of vaccine in year
1, a greater difference versus placebo was  observed at the second
versus ﬁrst sample collection (approximately 2 months versus 1
month postvaccination). When the percentage of subjects with a
≥4-fold increase was  evaluated, a similar pattern was observed,
although response rates were lower. For LAIV and placebo recipi-
ents respectively, response rates were 26–39% versus 12–30% for
6796 C.S.  Ambrose et al. / Vaccine 30 (2012) 6794– 6801
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/H1N1, 33–48% versus 20–27% for A/H3N2, and 46–59% versus
4–38% for B. When subjects were stratiﬁed by baseline serosta-
us, similar IgA responses were observed among seronegative and
eropositive subjects.
Postvaccination GMFRs for strain-speciﬁc IgA ratios among LAIV
ecipients after 2 doses of vaccine in year 1 ranged from 1.4 to
.2, compared to 0.5–2.0 among placebo recipients (Table 1). In
ear 2, GMFRs ranged from 1.2 to 4.6 among LAIV recipients and
.8–2.2 among placebo recipients (Table 1). Postvaccination GMFRs
n absolute strain-speciﬁc IgA, uncorrected for total IgA, trended
igher than postvaccination GMFRs in strain-speciﬁc IgA ratios.
.3.  Increases in total IgAAmong  LAIV and placebo recipients, total IgA increased from
revaccination to postvaccination by 1.0- to 2.4-fold in year 1 and
.7- to 1.2-fold in year 2 (Table 2). Year 1 of study 3 was responsiblecination with LAIV or placebo. *P < 0.05 vs placebo comparator, †P < 0.01 vs placebo
for  the greatest observed responses for LAIV and placebo recipi-
ents and 4 of the 5 statistically signiﬁcant GMFRs. Because of the
observed increases in total IgA from prevaccination to postvacci-
nation in both placebo and vaccine recipients in year 1 of study 3,
subject-level data by site were reviewed. In study 3, but not in stud-
ies 1 and 2, the total IgA content in year 1 prevaccination samples
was lower among the initial subjects enrolled at sites and higher
among subjects enrolled subsequently; linear regression analysis
controlling for site showed that total IgA content in prevaccina-
tion samples increased signiﬁcantly over calendar time in study 3
(P = 0.002).
3.4. Relationship between IgA and HAI responsesAcross studies, data for both HAI and IgA responses following
receipt of 2 doses was  available for 392 LAIV recipients and 213
placebo recipients in year 1. Four-fold increases in HAI antibody
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Table 1
Postvaccination GMFRs in ratios of strain-speciﬁc to total IgA for LAIV and placebo by study.
Strain Study 1 Study 2 Study 3
Year 1, LAIV/LAIV
(N  = 107)
Year 1, Pbo/Pbo
(N  = 76)
Year 1, LAIV/LAIV
(N  = 64)
Year 1, Pbo/Pbo
(N  = 37)
Year 1, LAIV/LAIV Year 1, LAIV/Pbo Year 1, Pbo/Pbo
Dose 1 (N = 109) Dose 2 (N = 113) Dose 1 (N = 116) Dose 2 (N = 112) Dose 1 (N = 111) Dose 2 (N = 107)
A/H1N1 1.4 (0.9, 2.2) 0.8 (0.5, 1.4) 2.1 (1.3, 3.4) 1.4 (0.7, 2.9) 0.9 (0.6, 1.3) 1.8 (1.2, 2.7)† 0.6 (0.4, 0.9) 0.8 (0.6, 1.3) 0.8 (0.5, 1.1) 0.6 (0.4, 0.8)
A/H3N2 3.6 (2.3, 5.5) † 0.9 (0.6, 1.4) 3.6 (2.1, 6.3)* 1.3 (0.7, 2.5) 1.1 (0.8, 1.6) 3.1 (2.0, 4.6)† 0.8 (0.5, 1.2) 0.9 (0.6, 1.5) 0.9 (0.6, 1.4) 0.8 (0.5, 1.2)
B 3.6 (2.2, 6.0) † 0.5 (0.3, 1.0) 6.2 (3.6, 10.8)* 2.0 (1.1, 3.9) 2.8 (1.8, 4.3)† 5.7 (3.8, 8.6)† 2.1 (1.3, 3.3)† 2.7 (1.6, 4.5)† 0.7 (0.5, 1.1) 0.6 (0.4, 0.9)
Strain Study 1 Study 2 Study 3
Year 2, LAIV
(N  = 94)
Year 2, Pbo
(N  = 81)
Year 2, LAIV
(N  = 24)
Year 2, Pbo (N = 17) Year 2, LAIV (N = 528) Year 2, Pbo (N = 263)
A/H1N1 1.9 (1.3, 2.7)* 0.9 (0.6, 1.4) 2.4 (1.1, 5.5) 1.1 (0.5, 2.3) 1.4 (1.2, 1.7)† 0.9 (0.7, 1.1)
A/H3N2  2.5 (1.6, 4.0)† 1.0 (0.6, 1.5) 2.3 (1.2, 4.5) 1.2 (0.5, 3.1) 1.6 (1.4, 1.9) † 0.9 (0.7, 1.1)
B  2.5 (1.7, 3.8)† 1.1 (0.8, 1.5) 4.6 (1.6, 13.7) 2.2 (1.0, 5.1) 1.2 (1.0, 1.4)† 0.8 (0.6, 1.0)
LAIV = live attenuated inﬂuenza vaccine; pbo = placebo.
* P < 0.05, LAIV compared with placebo.
† P < 0.01, LAIV compared with placebo.
Table  2
Postvaccination GMFR in total IgA for LAIV and placebo by study.
Study 1 Study 2 Study 3
Year 1, LAIV/LAIV
(N  = 107)
Year 1, Pbo/Pbo
(N  = 76)
Year  1, LAIV/LAIV
(N  = 64)
Year  1, Pbo/Pbo
(N  = 37)
Year  1, LAIV/LAIV Year 1, LAIV/Pbo Year 1, Pbo/Pbo
Dose 1 (N = 109) Dose 2 (N = 113) Dose 1 (N = 116) Dose 2 (N = 112) Dose 1 (N = 111) Dose 2 (N = 107)
1.2 (0.8, 1.8) 1.9 (1.2, 3.0) 1.2 (0.9, 1.7) 1.0 (0.5, 1.8) 1.9 (1.3, 2.7) 1.4 (0.96, 2.1) 2.4 (1.6, 3.6) 2.0 (1.3, 2.9) 1.3 (0.9, 1.9) 1.6 (1.1, 2.4)
Study 1 Study 2 Study 3
Year 2, LAIV (N = 94) Year 2, Pbo
(N  = 81)
Year  2, LAIV
(N  = 24)
Year  2, Pbo
(N  = 17)
Year  2, LAIV (N = 528) Year 2, Pbo (N = 263)
1.1 (0.9, 1.5) 1.0 (0.7, 1.4) 1.2 (0.7, 2.1) 0.7 (0.4, 1.5) 1.2 (0.98, 1.4) 1.2 (0.96, 1.5)
LAIV = live attenuated inﬂuenza vaccine; pbo = placebo.
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iter for A/H1N1 were observed for 61% of LAIV recipients compared
o 13% of placebo recipients (P < 0.001); for A/H3N2 and B, responses
ere 74% versus 16% (P < 0.001) and 76% versus 12% (P < 0.001) for
AIV versus placebo recipients, respectively. Among LAIV recipi-
nts, IgA responses were more frequently seen among subjects with
n HAI response. Across studies, IgA responses to A/H1N1 were
bserved among 48% of subjects with a 4-fold HAI response, com-
ared to 33% of those without a 4-fold HAI response (P < 0.001). For
/H3N2 and B, the proportions were 57% versus 37% (P < 0.001) and
5% versus 39% (P < 0.001), respectively. Among placebo recipients,
gA response rates were generally comparable for subjects with and
ithout a HAI response: 22% versus 30% for A/H1N1 (P = 0.5), 41%
ersus 28% for A/H3N2 (P = 0.2), and 31% versus 34% for B (P = 0.8).
In year 2, 360 placebo recipients and 633 LAIV recipients had
ata for both HAI and IgA responses. For A/H1N1, A/H3N2 and
, HAI responses were 48% versus 16% (P < 0.001), 42% versus
6% (P < 0.001), and 29% versus 10% (P < 0.001) for LAIV versus
lacebo recipients, respectively. For LAIV recipients, IgA responses
o A/H1N1, A/H3N2, and B were observed among 48% versus
5% (P < 0.001), 51% versus 38% (P < 0.001) and 48% versus 36%
P < 0.001) of those with and without a HAI response, respectively.
s in year 1, IgA responses among placebo recipients were gener-
lly comparable for subjects with and without a HAI response: 21%
ersus 33% for A/H1N1 (P = 0.1), 26% versus 28% for A/H3N2 (P = 0.9),
nd 42% versus 27% for B (P = 0.1).
.5.  Relationship between igA and inﬂuenza illness
Based on pooled data from all 3 studies, in years 1 and 2, the
ean postvaccination strain-speciﬁc to total IgA ratio was  3.1-fold
igher (P < 0.01) and 2.0-fold higher (P = 0.03) among LAIV recip-
ents with no culture-conﬁrmed inﬂuenza illness compared with
AIV recipients who developed culture-conﬁrmed inﬂuenza illness
Table 3). For each individual study and each type/subtype, mean
ostvaccination IgA ratios were generally higher among LAIV recip-
ents with no evidence of inﬂuenza illness, although no individual
omparison reached statistical signiﬁcance.
When the analysis was restricted to culture-conﬁrmed illness
ue to vaccine-matched strains, a 3.0-fold difference in IgA ratios
etween those with and without illness was still present among
AIV recipients in year 1 (P = 0.02). However, in year 2, there were
ery few subjects who developed vaccine-matched inﬂuenza ill-
ess (N = 13); the IgA ratio was 1.4-fold higher among those without
nﬂuenza illness but this difference was not statistically signiﬁ-
ant (P = 0.59). In year 2 of study 3, there was a high incidence
f inﬂuenza illness due to antigenically mismatched inﬂuenza B
trains, due to signiﬁcant circulation of viruses from the inﬂuenza
 lineage not included in the vaccine; the B/Yamagata lineage
train B/Victoria/504/2000 was included in the vaccine but B/Hong
ong/1351/2002-like viruses of the B/Victoria lineage circulated. In
ear 2 of study 3, the mean IgA ratio against the vaccine-matched
nﬂuenza B antigen was 1.8-fold higher among those subjects with-
ut illness compared with those with illness due to opposite lineage
 strains (P = 0.15).
Among placebo recipients in years 1 and 2, there was no trend
f higher IgA ratios among subjects without inﬂuenza illness (year
 N = 418; year 2 N = 498) relative to those with inﬂuenza illness
year 1 N = 34; year 2 N = 34); no comparisons were statistically
igniﬁcant (Supplementary Table 1).
. DiscussionThis analysis of IgA responses from 3 clinical studies in young
hildren conﬁrms that LAIV induces measurable strain-speciﬁc
gA and demonstrates that these responses are associated with30 (2012) 6794– 6801
protection  from subsequent inﬂuenza illness. IgA response rates
were similar among subjects with and without prior exposure
to inﬂuenza, as measured by baseline HAI antibody. For LAIV
recipients, postvaccination strain-speciﬁc to total IgA ratios were
consistently higher among those without inﬂuenza illness; thus
higher amounts of strain-speciﬁc IgA appeared to protect the chil-
dren from developing inﬂuenza illness. These ﬁndings are expected
given that LAIV is a mucosal vaccine; however, they have not been
previously demonstrated in large clinical studies.
The association between nasal strain-speciﬁc IgA and the inci-
dence of inﬂuenza illness was consistently observed in years 1 and
2. The increased IgA response following 2 doses versus 1 dose of
vaccine in study 3 also demonstrates that LAIV-induced mucosal
antibody responses can be boosted with revaccination, consis-
tent with data demonstrating enhanced clinical efﬁcacy following
revaccination [20]. However, the observed increases in IgA among
LAIV recipients were of moderate magnitude and highly variable
and substantial responses were observed among placebo recipi-
ents. This high variability is expected given that variation in nasal
secretions and sample collection can lead to signiﬁcant variabil-
ity in sample volume and quality; this phenomenon explains the
response rates observed among placebo recipients. As a result, the
current data demonstrate that evaluations of strain-speciﬁc IgA
responses in LAIV versus placebo recipients can provide a posi-
tive marker of vaccine-induced immunity but do not fully explain
LAIV-induced protection from inﬂuenza illness.
A previous study by Boyce et al. demonstrated higher postvac-
cination IgA responses among pediatric LAIV recipients than the
current analysis; IgA responses were observed in 62–85% of LAIV
recipients compared to 0–33% of placebo recipients [27]. The higher
response seen may  be due to the small sample, more consistent
sampling in a single study center, or slight differences in assay
methodology. Additionally, Boyce et al. evaluated IgA an average
of 82 days following vaccination, in contrast to the 56 days used in
the studies presented here. Data from study 3 suggest that LAIV-
induced strain-speciﬁc IgA responses continue to increase over
time, as responses in subjects who  received a single dose of LAIV
were more apparent at 2 months versus 1 month after vaccina-
tion.
In adults vaccinated with LAIV, IgA responses have been less
consistent and more modest than the responses observed in chil-
dren. In previous exploratory studies conducted in adults, IgA
response rates in LAIV recipients ranged from 10% to 40%, and
in many cases, responses were not different from those observed
among placebo recipients. However, 1 study reported that 80–100%
of adult LAIV recipients achieved a ≥2-fold increase from baseline in
strain-speciﬁc IgA antibodies [36]. However, the IgA analysis lacked
a control group and thus it is difﬁcult to interpret the high observed
response.
Based on the detection of increased inﬂuenza-speciﬁc IgG and
IgA circulating antibody-secreting B cells 1–2 weeks following LAIV
vaccination with minimal subsequent increases in serum antibody
and systemic memory B cells, Sasaki et al. proposed that LAIV pro-
vides protective immunity through a local B-cell memory response
in the upper respiratory tract [26]. This mechanism is consistent
with the current analysis and represents a plausible explanation
of LAIV-induced antibody-mediated immunity, which is critical to
block inﬂuenza virus infection [1]. However, it is clear that other
aspects of the immune system contribute to LAIV-induced pro-
tection from inﬂuenza. In the current analysis and in a study by
Boyce et al., the highest IgA responses were directed against the B
strains followed by A/H3N2 [27]; however, LAIV has demonstrated
similar and high efﬁcacy in children against all 3 types/subtypes
[11,37]. Studies have demonstrated that LAIV-induced immunity
can also be partially explained by T-cell immunity [17,28,29,38] and
serum antibody responses [39]. Stimulation of innate immunity
C.S. Ambrose et al. / Vaccine 30 (2012) 6794– 6801 6799
Table  3
Relationship between postvaccination ratio of strain-speciﬁc to total IgA and the incidence of culture-conﬁrmed inﬂuenza by study and type/subtype: LAIV recipients.
Type/subtype Study Subjects without Inﬂuenza Subjects with Inﬂuenza P
N IgA ratio, GM N IgA ratio, GM
Year 1
A/H1N1 1 102 0.31 2 0.19 0.78
A/H3N2 1 102 0.54  3 0.16  0.24
A/H3N2 3 210  0.05 18 0.03 0.38
A/H3N2 Pooled  312 0.10 21 0.04 0.05
B  1 102 1.26 4 0.68 0.58
B  2 67 0.30 2 0.05 0.14
B  3 210 0.11 3 0.04 0.36
B Pooled 379 0.26  9 0.15  0.46
Pooled Pooled 379 0.18  32 0.06  <0.01
Year  2
A/H1N1 3 374 0.05 4 0.01 0.06
A/H3N2  1 89 0.32 5 0.09 0.16
A/H3N2  2 23 0.74 1 0.77 0.99
A/H3N2  3 374 0.10 2 0.79 0.14
A/H3N2  Pooled 486 0.13 8 0.21 0.55
B  1 89 0.31 1 0.35 0.95
B 3 374 0.06  33 0.03  0.11
B  Pooled 463 0.08 34 0.04 0.03
Pooled Pooled  486 0.09 45 0.04 0.03
Years  1 and 2 combined
A/H1N1  Pooled 476 0.07 6 0.02 0.19
A/H3N2  Pooled 658 0.12 29 0.06 0.08
B Pooled 702 0.14  43 0.05 <0.01
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M = geometric mean.
ia interferon and natural killer cells may  also contribute to LAIV-
nduced protection, particularly when inﬂuenza circulates shortly
fter vaccination [38,40–42]. As an attenuated live virus vaccine, it
ould be expected that LAIV would induce a multi-faceted immune
esponse, similar to that induced by wild-type inﬂuenza infection
nd other live virus vaccines [1]. It is likely that no single compo-
ent of the response can fully explain the protective effect induced
y LAIV.
Under the classiﬁcation of correlates of protection for vac-
ination proposed by Plotkin [43,44], the association between
AIV-induced protection and measured IgA responses would be
est classiﬁed as a relative co-correlate of protection. The relative
o-correlate classiﬁcation is appropriate because strain-speciﬁc IgA
esponses were associated with protection in LAIV recipients, but
he level of response observed varied by strain and study and
accine-induced protection has been shown to be correlated with
ther components of the immune response. Additionally, it is worth
oting that no relationship between strain-speciﬁc IgA ratios and
nﬂuenza illness incidence was observed among placebo recipients,
hich is a requirement for a more robust correlate of protection
43,44]. However, this lack of an association among placebo recip-
ents is likely due to limited baseline strain-speciﬁc anti-inﬂuenza
ucosal immunity among the study subjects given their young
ge.
Because of the high degree of variability observed, IgA would
ot be appropriate for evaluations requiring a precise quanti-
ative assessment of the magnitude of LAIV-induced immune
esponses. In contrast, although they do not represent a correlate
f protection, serum antibody levels following LAIV can be more
onsistently evaluated as the serum compartment is not subject
o the same variability in content and sampling. For this reason,
erum antibody responses following LAIV are the preferred method
or evaluating the immunologic comparability of vaccine formu-
ations or administration schemes [13,21,45–49]. In the current
nalysis, IgA and HAI responses were correlated, as IgA responses
ere more frequently observed among subjects with a HAI
esponse.76 0.05 <0.01
The primary limitation of the current analysis is the small size
of the study cohorts. Although the pooled sample enabled an
examination of the relationship between IgA and the incidence
of inﬂuenza illness, the analysis would have beneﬁted from larger
cohort populations. Averaging of IgA ratios across studies can also
be problematic due to variability in values across types/subtypes
and across studies. However, it is reassuring that the conclusions
of the pooled analyses were supported by similar and consistent
trends by study and type/subtype. In the analysis of the relationship
between IgA and culture-conﬁrmed inﬂuenza illness, it is possible
that subjects without culture-conﬁrmed inﬂuenza illness still expe-
rienced inﬂuenza infection; however, identiﬁcation of these cases
would likely have strengthened the observed relationship. Addi-
tionally, the assay was speciﬁc to IgA and did not evaluate nasal
IgM or IgG antibody, which can also contribute to mucosal immu-
nity [1]; a postvaccination increase in nasal wash IgG was observed
in a prior study of LAIV [36].
In study 3, signiﬁcant increases in total IgA were observed
between baseline and postvaccination samples. Among prevacci-
nation samples, which would not be subject to vaccine-induced
effects, subjects who enrolled later had signiﬁcantly higher total
IgA, suggesting that site sample collection technique improved
over time. This observation supports the practice of providing
interspecimen standardization by reporting IgA values as ratios
of speciﬁc to total IgA. A postvaccination rise in total IgA has also
been reported following intranasal measles vaccination; however,
the study lacked a placebo control and thus it was not possible to
determine whether the total IgA increase was vaccine-attributable
[50].
In conclusion, results from 3 clinical studies in young children
demonstrated that LAIV induced measurable strain-speciﬁc IgA
after vaccination and that IgA responses are associated with pro-
tection from subsequent inﬂuenza illness. However, the inherent
heterogeneity in nasal antibody levels and variability in nasal spec-
imen collection hinders the precise evaluation of mucosal antibody
responses, and measured IgA responses do not fully explain LAIV-
induced protection.
6 ccine 
S
e
a
m
A
A
p
c
t
t
A
L
L
m
a
m
v
C
f
A
f
2
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[800 C.S.  Ambrose et al. / Va
ources of support
This  study was sponsored by MedImmune, LLC. Authors
mployed by MedImmune, LLC were involved in the study design,
nalysis, and interpretation of data, and in the preparation of the
anuscript.
cknowledgments
Contributors: Study concept and design: Drs. Ambrose and Wu.
cquisition of data: Drs. Ambrose and Wu.  Analysis and inter-
retation of data: all authors. Drafting of the manuscript and
ritical revision of the manuscript for important intellectual con-
ent: all authors. Statistical analysis: Dr. Wu.  All authors approved
he ﬁnal manuscript for submission. Financial disclosures: Drs.
mbrose, Wu,  Jones, and Mallory are employees of MedImmune,
LC, Gaithersburg, MD.
Funding/support: This research was funded by MedImmune,
LC. Role of the sponsor: All authors are employees of MedIm-
une, LLC who worked collaboratively in the design of the analysis
nd interpretation of the data, and reviewed and approved the
anuscript. Additional contributions: Editorial assistance was pro-
ided by Susan E. DeRocco, PhD, and Gerard P. Johnson, PhD, of
omplete Healthcare Communications, Inc. (Chadds Ford, PA) and
unded by MedImmune, LLC.
ppendix A. Supplementary data
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.vaccine.
012.09.018.
eferences
[1] Cox RJ, Brokstad KA, Ogra P. Inﬂuenza virus: immunity and vaccination strate-
gies.  Comparison of the immune response to inactivated and live, attenuated
inﬂuenza  vaccines. Scand J Immunol 2004;59:1–15.
[2] Wilkinson TM,  Li CK, Chui CS, Huang AK, Perkins M,  Liebner JC, et al. Preexis-
ting  inﬂuenza-speciﬁc CD4(+) T cells correlate with disease protection against
inﬂuenza  challenge in humans. Nat Med  2012;18:274–80.
[3] Murphy BR, Clements ML.  The systemic and mucosal immune response of
humans  to inﬂuenza A virus. Curr Top Microbiol Immunol 1989;146:107–16.
[4] Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al. Preven-
tion  and control of inﬂuenza with vaccines: recommendations of the Advisory
Committee  on Immunization Practices (ACIP), 2010. MMWR  Recomm Rep
2010;59:1–62.
[5]  FluMist® (Inﬂuenza Virus Vaccine Live, Intranasal, Full prescribing informa-
tion).  Full prescribing information. Gaithersburg, MD:  MedImmune, LLC; 2011.
[6] Ambrose CS, Wu X, Knuf M, Wutzler P. The efﬁcacy of intranasal live attenuated
inﬂuenza  vaccine in children 2 through 17 years of age: a meta-analysis of 8
randomized  controlled studies. Vaccine 2012;30:886–92.
[7]  De Villiers PJ, Steele AD, Hiemstra LA, Rappaport R, Dunning AJ, Gruber WC,
et  al. Efﬁcacy and safety of a live attenuated inﬂuenza vaccine in adults 60
years  of age and older. Vaccine 2009;28:228–34.
[8]  Treanor JJ, Betts RF. Evaluation of live, cold-adapted inﬂuenza A and B virus
vaccines  in elderly and high-risk subjects. Vaccine 1998;16:1756–60.
[9] Ashkenazi S, Vertruyen A, Aristegui J, Esposito S, McKeith DD, Klemola T, et al.
Superior  relative efﬁcacy of live attenuated inﬂuenza vaccine compared with
inactivated  inﬂuenza vaccine in young children with recurrent respiratory tract
infections. Pediatr Infect Dis J 2006;25:870–9.
10]  Fleming DM,  Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al.
Comparison  of the efﬁcacy and safety of live attenuated cold-adapted inﬂuenza
vaccine,  trivalent, with trivalent inactivated inﬂuenza virus vaccine in children
and  adolescents with asthma. Pediatr Infect Dis J 2006;25:860–9.
11] Ambrose CS, Levin MJ,  Belshe RB. The relative efﬁcacy of trivalent live attenu-
ated  and inactivated inﬂuenza vaccines in children and adults. Inﬂuenza Other
Respir  Viruses 2011;5:67–75.
12] Belshe RB, Edwards KM,  Vesikari T, Black SV, Walker RE, Hultquist M,  et al. Live
attenuated  versus inactivated inﬂuenza vaccine in infants and young children.
N  Engl J Med  2007;356:685–96.13] Breiman RF, Brooks WA,  Goswami D, Lagos R, Borja-Tabora C, Lanata CF,
et  al. A multinational, randomized, placebo-controlled trial to assess the
immunogenicity, safety, and tolerability of live attenuated inﬂuenza vaccine
coadministered with oral poliovirus vaccine in healthy young children. Vaccine
2009;27:5472–9.
[30 (2012) 6794– 6801
14]  Bracco Neto H, Farhat CK, Tregnaghi MW,  Madhi SA, Razmpour A, Palladino G,
et  al. Efﬁcacy and safety of 1 and 2 doses of live attenuated inﬂuenza vaccine
in  vaccine-naive children. Pediatr Infect Dis J 2009;28:365–71.
15] Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W,  Walker RE. Shedding and
immunogenicity  of live attenuated inﬂuenza vaccine virus in subjects 5–49
years  of age. Vaccine 2008;26:4940–6.
16] Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC,  Piedra P, et al. The
efﬁcacy  of live attenuated, cold-adapted, trivalent, intranasal inﬂuenzavirus
vaccine in children. N Engl J Med 1998;338:1405–12.
17] Forrest BD, Pride MW,  Dunning AJ, Capeding MR,  Chotpitayasunondh T, Tam
JS,  et al. Correlation of cellular immune responses with protection against
culture-conﬁrmed inﬂuenza virus in young children. Clin Vaccine Immunol
2008;15:1042–53.
18] Lee  MS,  Mahmood K, Adhikary L, August MJ,  Cordova J, Cho I, et al. Measuring
antibody  responses to a live attenuated inﬂuenza vaccine in children. Pediatr
Infect  Dis J 2004;23:852–6.
19] King Jr JC, Lagos R, Bernstein DI, Piedra PA, Kotloff K, Bryant M, et al. Safety and
immunogenicity of low and high doses of trivalent live cold-adapted inﬂuenza
vaccine  administered intranasally as drops or spray to healthy children. J Infect
Dis  1998;177:1394–7.
20] Tam JS, Capeding MR,  Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM,  et al.
Efﬁcacy  and safety of a live attenuated, cold-adapted inﬂuenza vaccine, triva-
lent  against culture-conﬁrmed inﬂuenza in young children in Asia. Pediatr
Infect  Dis J 2007;26:619–28.
21] Zangwill KM,  Droge J, Mendelman P, Marcy SM,  Partridge S, Chiu CY, et al.
Prospective,  randomized, placebo-controlled evaluation of the safety and
immunogenicity of three lots of intranasal trivalent inﬂuenza vaccine among
young  children. Pediatr Infect Dis J 2001;20:740–6.
22]  Grifﬁn MR, Walker FJ, Iwane MK, Weinberg GA, Staat MA,  Erdman DD. Epi-
demiology  of respiratory infections in young children: insights from the new
vaccine  surveillance network. Pediatr Infect Dis J 2004;23:S188–92.
23] Mallory RM,  Malkin E, Ambrose CS, Bellamy T, Shi L, Yi T, et al. Safety and
immunogenicity following administration of a live attenuated monovalent
2009  H1N1 inﬂuenza vaccine to children and adults in two randomized con-
trolled  trials. PLoS ONE 2010;5:e13755.
24] Edwards KM,  Dupont WD,  Westrich MK,  Plummer Jr WD,  Palmer PS, Wright
PF.  A randomized controlled trial of cold-adapted and inactivated vaccines for
the  prevention of inﬂuenza A disease. J Infect Dis 1994;169:68–76.
25] Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, Iacuzio D, et al. Evalua-
tion  of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) inﬂuenza
vaccines  in prevention of virus infection and illness following challenge of
adults  with wild-type inﬂuenza A (H1N1), A (H3N2), and B viruses. Vaccine
1999;18:899–906.
26] Sasaki  S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW,  et al. Com-
parison  of the inﬂuenza virus-speciﬁc effector and memory B-cell responses
to  immunization of children and adults with live attenuated or inactivated
inﬂuenza virus vaccines. J Virol 2007;81:215–28.
27] Boyce TG, Gruber WC,  Coleman-Dockery SD, Sannella EC, Reed GW,  Wolff
M,  et al. Mucosal immune response to trivalent live attenuated intranasal
inﬂuenza vaccine in children. Vaccine 1999;18:82–8.
28]  Basha S, Hazenfeld S, Brady RC, Subbramanian RA. Comparison of antibody and
T-cell responses elicited by licensed inactivated- and live-attenuated inﬂuenza
vaccines  against H3N2 hemagglutinin. Hum Immunol 2011;72:463–9.
29] Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM,  et al. Live
and  inactivated inﬂuenza vaccines induce similar humoral responses, but only
live  vaccines induce diverse T-cell responses in young children. J Infect Dis
2011;204:845–53.
30]  He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW,  Lewis DB, et al. Cel-
lular  immune responses in children and adults receiving inactivated or live
attenuated  inﬂuenza vaccines. J Virol 2006;80:11756–66.
31]  Mazanec MB,  Coudret CL, Fletcher DR. Intracellular neutralization of inﬂuenza
virus  by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol
1995;69:1339–43.
32] Brokstad  KA, Cox RJ, Eriksson JC, Olofsson J, Jonsson R, Davidsson A. High preva-
lence  of inﬂuenza speciﬁc antibody secreting cells in nasal mucosa. Scand J
Immunol  2001;54:243–7.
33] He Y, Abid A, Fisher R, Eller N, Mikolajczyk M, Welliver Sr RC,
et  al. Mucosal antibody responses are directed by viral burden in chil-
dren  with acute inﬂuenza infection. Inﬂuenza Other Respi Viruses 2012,
http://dx.doi.org/10.1111/j.1750-2659.2012.00346.x.
34] Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection pro-
vided  by inﬂuenza virus infection and their application to vaccines. Jpn J Infect
Dis  2005;58:195–207.
35] Vesikari T, Fleming DM,  Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport
R,  et al. Safety, efﬁcacy, and effectiveness of cold-adapted inﬂuenza vaccine-
trivalent  against community-acquired, culture-conﬁrmed inﬂuenza in young
children  attending day care. Pediatrics 2006;118:2298–312.
36]  Hammitt LL, Bartlett JP, Li S, Rahkola J, Lang N, Janoff EN, et al. Kinetics of
viral  shedding and immune responses in adults following administration of
cold-adapted  inﬂuenza vaccine. Vaccine 2009;27:7359–66.
37]  Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, et al.
Efﬁcacy  of live attenuated inﬂuenza vaccine in children: a meta-analysis of nine
randomized  clinical trials. Vaccine 2009;27:1101–10.
38]  Lanthier PA, Huston GE, Moquin A, Eaton SM,  Szaba FM, Kummer LW,  et al.
Live  attenuated inﬂuenza vaccine (LAIV) impacts innate and adaptive immune
responses.  Vaccine 2011;29:7849–56.
ccine 
[
[
[
[
[
[
[
[
[
[
[C.S. Ambrose et al. / Va
39]  Clements ML,  Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies
associated  with resistance to experimental challenge with inﬂuenza A wild-
type  virus. J Clin Microbiol 1986;24:157–60.
40] Zhu W,  Higgs BW,  Morehouse C, Streicher K, Ambrose CS, Woo  J, et al. A whole
genome  transcriptional analysis of the early immune response induced by
live  attenuated and inactivated inﬂuenza vaccines in young children. Vaccine
2010;28:2865–76.
41] Horvath  KM,  Herbst M,  Zhou H, Zhang H, Noah TL, Jaspers I. Nasal lavage natural
killer  cell function is suppressed in smokers after live attenuated inﬂuenza
virus.  Respir Res 2011;12:102.
42] Piedra PA, Gaglani MJ,  Kozinetz CA, Herschler GB, Fewlass C, Harvey D, et al.
Trivalent  live attenuated intranasal inﬂuenza vaccine administered during the
2003–2004  inﬂuenza type A (H3N2) outbreak provided immediate, direct, and
indirect  protection in children. Pediatrics 2007;120:e553–64.43]  Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis
2008;47:401–9.
44]  Qin L, Gilbert PB, Corey L, McElrath MJ,  Self SG. A framework for
assessing immunological correlates of protection in vaccine trials. J Infect Dis
2007;196:1304–12.
[30 (2012) 6794– 6801 6801
45]  Nolan T, Bernstein DI, Block S, Hilty M,  Keyserling HL, Marchant C, et al. Safety
and  immunogenicity of concurrent live attenuated inﬂuenza vaccine with
measles-mumps-rubella and varicella vaccines in infants 12 to 15 months of
age.  Pediatrics 2008;121:508–16.
46] Block SL, Falloon J, Hirschﬁeld J, Krilov L, Dubovsky F, Yi T, et al. The immuno-
genicity  and safety of a quadrivalent live attenuated inﬂuenza vaccine in
children.  Pediatr Infect Dis J 2012;31:745–51.
47] Nolan T, Lee MS,  Cordova JM,  Cho I, Walker RE, August MJ, et al. Safety and
immunogenicity of a live-attenuated inﬂuenza vaccine blended and ﬁlled at
two  manufacturing facilities. Vaccine 2003;21:1224–31.
48]  Block SL, Reisinger KS, Hultquist M,  Walker RE. Comparative immunogenicities
of  frozen and refrigerated formulations of live attenuated inﬂuenza vaccine in
healthy  subjects. Antimicrob Agents Chemother 2007;51:4001–8.
49] Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J. A randomized, double-blind
noninferiority study of quadrivalent live attenuated inﬂuenza vaccine in adults.
Vaccine  2011;29:9391–7.
50] Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Munoz A, et al. Mucosal
IgA  responses in healthy adult volunteers following intranasal spray delivery
of  a live attenuated measles vaccine. Clin Vaccine Immunol 2011;18:355–61.
